|
1 Indications And Usage Zoladex Is A Gonadotropin Releasing Hormone (Gnrh) Agonist Indicated For: Use In Combination With Flutamide For The Management Of Locally Confined Carcinoma Of The Prostate ( 1.1 ) Use As Palliative Treatment Of Advanced Carcinoma Of The Prostate ( 1.2 ) 1.1 Stage B2-C Prostatic Carcinoma Zoladex Is Indicated For Use In Combination With Flutamide For The Management Of Locally Confined Stage T2b-T4 (Stage B2-C) Carcinoma Of The Prostate. Treatment With Zoladex And Flutamide Should Start 8 Weeks Prior To Initiating Radiation Therapy And Continue During Radiation Therapy [See Dosage And Administration ( 2.1 ) And Clinical Studies ( 14.1 )]. 1.2 Prostatic Carcinoma Zoladex Is Indicated In The Palliative Treatment Of Advanced Carcinoma Of The Prostate [See Dosage And Administration ( 2.2 ) And Clinical Studies ( 14.2 )]. In Controlled Studies Of Patients With Advanced Prostatic Cancer Comparing Zoladex 3.6 Mg To Orchiectomy, The Long-Term Endocrine Responses And Objective Responses Were Similar Between The Two Treatment Arms. Additionally, Duration Of Survival Was Similar Between The Two Treatment Arms In A Major Comparative Trial. In Controlled Studies Of Patients With Advanced Prostatic Cancer, Zoladex 10.8 Mg Implant Produced Pharmacodynamically Similar Effect In Terms Of Suppression Of Serum Testosterone To That Achieved With Zoladex 3.6 Mg Implant. Clinical Outcome Similar To That Produced With The Use Of The Zoladex 3.6 Mg Implant Administered Every 28 Days Is Predicted With The Zoladex 10.8 Mg Implant Administered Every 12 Weeks. The Automatic Safety Feature Of The Syringe Aids In The Prevention Of Needlestick Injury.
|